Cipla Limited has launched Ciposcillo®, an advanced oscillometer designed for accurately and precisely assessing respiratory mechanics.

The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo is CDSCO approved and ISO certified. 

Ciposcillo combines precision, portability and clinically validated technology to better enable clinicians to assess patients across diverse healthcare settings. Importantly, the oscillometer can assess respiratory functions using normal, tidal breathing, eliminating the need for forceful patient effort.

This makes it particularly suitable for use in elderly patients, young children, and others who may not be able to perform effort-dependent tests such as spirometry. 

Achin Gupta, Managing Director and Global CEO, Cipla said, “At Cipla, innovation is central to how we address patient needs across the healthcare continuum, from therapies to diagnostics. With Ciposcillo, we are not only bringing advanced diagnostic technology closer to clinicians to empower better decision-making, but also enabling a simpler, effort-independent approach that makes it accessible across age groups and care settings."